SI2684955T1 - A method for promoting angiogenesis, vascular or repair of the vessels, or for inhibiting tumor angiogenesis - Google Patents
A method for promoting angiogenesis, vascular or repair of the vessels, or for inhibiting tumor angiogenesis Download PDFInfo
- Publication number
- SI2684955T1 SI2684955T1 SI200831894T SI200831894T SI2684955T1 SI 2684955 T1 SI2684955 T1 SI 2684955T1 SI 200831894 T SI200831894 T SI 200831894T SI 200831894 T SI200831894 T SI 200831894T SI 2684955 T1 SI2684955 T1 SI 2684955T1
- Authority
- SI
- Slovenia
- Prior art keywords
- antisense molecule
- mir
- group
- sequence
- use according
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract 3
- 206010028980 Neoplasm Diseases 0.000 title claims 2
- 230000033115 angiogenesis Effects 0.000 title 2
- 230000002401 inhibitory effect Effects 0.000 title 1
- 230000001737 promoting effect Effects 0.000 title 1
- 230000000692 anti-sense effect Effects 0.000 claims abstract 16
- 108091059456 miR-92-1 stem-loop Proteins 0.000 claims abstract 11
- 108091084336 miR-92-2 stem-loop Proteins 0.000 claims abstract 11
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 2
- 102100023870 YLP motif-containing protein 1 Human genes 0.000 claims 4
- 238000007385 chemical modification Methods 0.000 claims 4
- 230000000295 complement effect Effects 0.000 claims 4
- 239000002773 nucleotide Substances 0.000 claims 4
- 125000003729 nucleotide group Chemical group 0.000 claims 4
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 2
- 208000031229 Cardiomyopathies Diseases 0.000 claims 2
- 206010061216 Infarction Diseases 0.000 claims 2
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CCCC(C)C HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 230000007574 infarction Effects 0.000 claims 2
- 230000000302 ischemic effect Effects 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 208000031225 myocardial ischemia Diseases 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000005747 tumor angiogenesis Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102007052114A DE102007052114B4 (de) | 2007-10-30 | 2007-10-30 | Verfahren zur Modulation der Funktion, des Wachstums oder der Differenzierung einer Zelle |
| EP13179144.4A EP2684955B1 (de) | 2007-10-30 | 2008-10-30 | Verfahren zur Förderung der Angiogenese, Vaskularisierung oder Gefäßreparatur oder zur Hemmung der Tumorangiogenese |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2684955T1 true SI2684955T1 (en) | 2018-01-31 |
Family
ID=40375407
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200831894T SI2684955T1 (en) | 2007-10-30 | 2008-10-30 | A method for promoting angiogenesis, vascular or repair of the vessels, or for inhibiting tumor angiogenesis |
| SI200831774A SI2217704T1 (sl) | 2007-10-30 | 2008-10-30 | Postopek za pospeševanje angiogeneze, vaskularizacije ali popravilo žil ali za zaviranje tumorske angiogeneze |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200831774A SI2217704T1 (sl) | 2007-10-30 | 2008-10-30 | Postopek za pospeševanje angiogeneze, vaskularizacije ali popravilo žil ali za zaviranje tumorske angiogeneze |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US8258113B2 (enExample) |
| EP (3) | EP2217704B1 (enExample) |
| JP (4) | JP5898843B2 (enExample) |
| CA (1) | CA2704290C (enExample) |
| CY (2) | CY1120360T1 (enExample) |
| DE (1) | DE102007052114B4 (enExample) |
| DK (2) | DK2684955T3 (enExample) |
| ES (2) | ES2618203T3 (enExample) |
| HR (2) | HRP20170346T1 (enExample) |
| HU (2) | HUE037494T2 (enExample) |
| LT (2) | LT2684955T (enExample) |
| NO (1) | NO2684955T3 (enExample) |
| PL (2) | PL2684955T3 (enExample) |
| PT (2) | PT2684955T (enExample) |
| SI (2) | SI2684955T1 (enExample) |
| WO (1) | WO2009056116A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITRM20030376A1 (it) | 2003-07-31 | 2005-02-01 | Univ Roma | Procedimento per l'isolamento e l'espansione di cellule staminali cardiache da biopsia. |
| US11660317B2 (en) | 2004-11-08 | 2023-05-30 | The Johns Hopkins University | Compositions comprising cardiosphere-derived cells for use in cell therapy |
| JP2010500011A (ja) | 2006-08-08 | 2010-01-07 | ガンサー ハートマン | ５’リン酸オリゴヌクレオチドの構造および使用 |
| DE102007052114B4 (de) | 2007-10-30 | 2011-01-05 | T2Cure Gmbh | Verfahren zur Modulation der Funktion, des Wachstums oder der Differenzierung einer Zelle |
| US9738680B2 (en) | 2008-05-21 | 2017-08-22 | Rheinische Friedrich-Wilhelms-Universität Bonn | 5′ triphosphate oligonucleotide with blunt end and uses thereof |
| US9845457B2 (en) | 2010-04-30 | 2017-12-19 | Cedars-Sinai Medical Center | Maintenance of genomic stability in cultured stem cells |
| US9249392B2 (en) | 2010-04-30 | 2016-02-02 | Cedars-Sinai Medical Center | Methods and compositions for maintaining genomic stability in cultured stem cells |
| US20130302293A1 (en) * | 2010-11-11 | 2013-11-14 | Keith A. Webster | Compositions, cells, kits and methods for autologous stem cell therapy |
| EP2508530A1 (en) | 2011-03-28 | 2012-10-10 | Rheinische Friedrich-Wilhelms-Universität Bonn | Purification of triphosphorylated oligonucleotides using capture tags |
| WO2013184527A1 (en) | 2012-06-05 | 2013-12-12 | Capricor, Inc. | Optimized methods for generation of cardiac stem cells from cardiac tissue and their use in cardiac therapy |
| EP2864482A4 (en) | 2012-06-21 | 2016-02-10 | Miragen Therapeutics Inc | OLIGONUCLEOTIDE INHIBITORS COMPRISING A BLOCKED NUCLEIC ACID PATTERN |
| EP3563859B1 (en) | 2012-08-13 | 2021-10-13 | Cedars-Sinai Medical Center | Cardiosphere-derived exosomes for tissue regeneration |
| EP2712870A1 (en) | 2012-09-27 | 2014-04-02 | Rheinische Friedrich-Wilhelms-Universität Bonn | Novel RIG-I ligands and methods for producing them |
| ES2606636T3 (es) * | 2013-01-24 | 2017-03-24 | Pierre Fabre Médicament S.A.S. | Composición que comprende un antagomir encapsulado |
| MX364814B (es) | 2013-03-15 | 2019-05-08 | Miragen Therapeutics Inc | Nucleosidos biciclicos unidos en puente. |
| US11439668B2 (en) | 2014-05-23 | 2022-09-13 | JangoBio, LLC | Methods to differentiate stem cells into hormone-producing cells |
| US11253549B2 (en) | 2014-05-23 | 2022-02-22 | JangoBio, LLC | Methods to rebalance the hypothalamic-pituitary-gonadal axis |
| CA2962444C (en) | 2014-10-03 | 2023-09-05 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of muscular dystrophy |
| US20160122762A1 (en) * | 2014-10-27 | 2016-05-05 | University Of Iowa Research Foundation | Methods of treating atherosclerosis |
| HK1249108A1 (zh) * | 2015-01-20 | 2018-10-26 | 米拉根医疗股份有限公司 | Mir-92抑制剂及其用途 |
| EP3402543B1 (en) | 2016-01-11 | 2021-09-08 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and exosomes secreted by such cells in the treatment of heart failure with preserved ejection fraction |
| US11351200B2 (en) | 2016-06-03 | 2022-06-07 | Cedars-Sinai Medical Center | CDC-derived exosomes for treatment of ventricular tachyarrythmias |
| CN107586784B (zh) * | 2016-07-08 | 2020-08-25 | 田小利 | 一种分离的rnasek基因及其在制备抗血管衰老药物中的应用 |
| WO2018057542A1 (en) | 2016-09-20 | 2018-03-29 | Cedars-Sinai Medical Center | Cardiosphere-derived cells and their extracellular vesicles to retard or reverse aging and age-related disorders |
| EP3612191B1 (en) | 2017-04-19 | 2026-03-11 | Cedars-Sinai Medical Center | Methods and compositions for treating skeletal muscular dystrophy |
| US11660355B2 (en) | 2017-12-20 | 2023-05-30 | Cedars-Sinai Medical Center | Engineered extracellular vesicles for enhanced tissue delivery |
| EP3749344A4 (en) | 2018-02-05 | 2022-01-26 | Cedars-Sinai Medical Center | METHODS OF THERAPEUTIC USE OF EXOSOMES AND Y-RNAS |
| US11674141B2 (en) * | 2018-02-28 | 2023-06-13 | National University Corporation Tokyo Medical And Dental University | Ischemic-lesion-site-specific gene therapy |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005013901A2 (en) * | 2003-07-31 | 2005-02-17 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding rnas |
| EP2471924A1 (en) * | 2004-05-28 | 2012-07-04 | Asuragen, INC. | Methods and compositions involving microRNA |
| US20090209621A1 (en) * | 2005-06-03 | 2009-08-20 | The Johns Hopkins University | Compositions and methods for decreasing microrna expression for the treatment of neoplasia |
| ES2425387T3 (es) * | 2006-07-13 | 2013-10-15 | The Ohio State University Research Foundation | Mir-106a para diagnosticar adenocarcinoma de colon de pronóstico de supervivencia pobre |
| US8466117B2 (en) * | 2006-07-28 | 2013-06-18 | The Johns Hopkins University | Compositions and methods for modulating angiogenesis |
| WO2008070082A2 (en) * | 2006-12-04 | 2008-06-12 | The Johns Hopkins University | Stem-progenitor cell specific micro-ribonucleic acids and uses thereof |
| WO2009004632A2 (en) * | 2007-07-05 | 2009-01-08 | Yeda Research And Development Co. Ltd. | Methods of identifying components of a biological pathway and use of said components in regulating diseases associated with altered cell proliferation |
| BRPI0813527A2 (pt) * | 2007-07-18 | 2014-12-30 | Univ Colorado | Expressão diferencial de micro-rnas em corações humanos que não falham versus que falham |
| DE102007052114B4 (de) | 2007-10-30 | 2011-01-05 | T2Cure Gmbh | Verfahren zur Modulation der Funktion, des Wachstums oder der Differenzierung einer Zelle |
-
2007
- 2007-10-30 DE DE102007052114A patent/DE102007052114B4/de active Active
-
2008
- 2008-10-30 ES ES08844273.6T patent/ES2618203T3/es active Active
- 2008-10-30 ES ES13179144.4T patent/ES2651287T3/es active Active
- 2008-10-30 US US12/739,876 patent/US8258113B2/en active Active
- 2008-10-30 PL PL13179144T patent/PL2684955T3/pl unknown
- 2008-10-30 CA CA2704290A patent/CA2704290C/en not_active Expired - Fee Related
- 2008-10-30 EP EP08844273.6A patent/EP2217704B1/de active Active
- 2008-10-30 WO PCT/DE2008/001759 patent/WO2009056116A1/de not_active Ceased
- 2008-10-30 DK DK13179144.4T patent/DK2684955T3/en active
- 2008-10-30 NO NO13179144A patent/NO2684955T3/no unknown
- 2008-10-30 HR HRP20170346TT patent/HRP20170346T1/hr unknown
- 2008-10-30 PT PT131791444T patent/PT2684955T/pt unknown
- 2008-10-30 EP EP13179144.4A patent/EP2684955B1/de active Active
- 2008-10-30 PL PL08844273T patent/PL2217704T3/pl unknown
- 2008-10-30 LT LTEP13179144.4T patent/LT2684955T/lt unknown
- 2008-10-30 SI SI200831894T patent/SI2684955T1/en unknown
- 2008-10-30 EP EP13179146.9A patent/EP2684956B1/de active Active
- 2008-10-30 PT PT88442736T patent/PT2217704T/pt unknown
- 2008-10-30 SI SI200831774A patent/SI2217704T1/sl unknown
- 2008-10-30 DK DK08844273.6T patent/DK2217704T3/en active
- 2008-10-30 LT LTEP08844273.6T patent/LT2217704T/lt unknown
- 2008-10-30 JP JP2010531412A patent/JP5898843B2/ja not_active Expired - Fee Related
- 2008-10-30 HU HUE13179144A patent/HUE037494T2/hu unknown
- 2008-10-30 HU HUE08844273A patent/HUE031559T2/hu unknown
-
2012
- 2012-08-08 US US13/569,786 patent/US8912158B2/en active Active
-
2014
- 2014-06-05 JP JP2014116545A patent/JP2014196317A/ja active Pending
- 2014-07-31 US US14/448,119 patent/US9279123B2/en active Active
-
2016
- 2016-02-10 US US15/040,487 patent/US9862949B2/en active Active
- 2016-06-24 JP JP2016125260A patent/JP2016199565A/ja active Pending
-
2017
- 2017-02-22 CY CY20171100245T patent/CY1120360T1/el unknown
- 2017-12-04 HR HRP20171874TT patent/HRP20171874T1/hr unknown
- 2017-12-06 CY CY20171101283T patent/CY1120226T1/el unknown
- 2017-12-14 JP JP2017239230A patent/JP2018083817A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2684955B1 (de) | Verfahren zur Förderung der Angiogenese, Vaskularisierung oder Gefäßreparatur oder zur Hemmung der Tumorangiogenese | |
| Ren et al. | Metformin carbon dots for promoting periodontal bone regeneration via activation of ERK/AMPK pathway | |
| Condorelli et al. | microRNAs in cardiovascular diseases: current knowledge and the road ahead | |
| HRP20210612T1 (hr) | Postupci i pripravci za specifičnu inhibiciju glikolat oksidaze (hao1) pomoću dvolančane rnk | |
| Bauersachs | Regulation of myocardial fibrosis by MicroRNAs | |
| Samanta et al. | MicroRNA: a new therapeutic strategy for cardiovascular diseases | |
| Islas et al. | A MicroRNA perspective on cardiovascular development and diseases: an update | |
| Joladarashi et al. | Small engine, big power: microRNAs as regulators of cardiac diseases and regeneration | |
| US20120238619A1 (en) | Micro-rna for the regulation of cardiac apoptosis and contractile function | |
| RU2014144630A (ru) | Композиции и способы ингибирования экспрессии гена alas1 | |
| JP2018529732A5 (enExample) | ||
| CO6241169A2 (es) | Metodos para el tratamiento de hipercolesterolemia | |
| Han et al. | A synthetic small molecule for targeted transcriptional activation of germ cell genes in a human somatic cell | |
| EP2031057A1 (en) | SENSE OLIGONUCLEOTIDE CAPABLE OF CONTROLLING THE EXPRESSION OF iNOS AND COMPOSITION COMPRISING THE SAME | |
| CN103380215A (zh) | 包含锁定核苷酸的微rna抑制剂 | |
| RU2013102545A (ru) | Связывающая vegfa си-рнк и способы лечения in vivo | |
| Sun et al. | Pioglitazone attenuates kidney fibrosis via miR-21-5p modulation | |
| CA3067910A1 (en) | Methods and compositions for controlling cardiac fibrosis and remodeling | |
| Ding et al. | The roles of MicroRNAs in tendon healing and regeneration | |
| Caño-Carrillo et al. | The role of ncRNAs in cardiac infarction and regeneration | |
| EP3452593B1 (en) | The incrna meg3 for therapy and diagnosis of cardiac remodelling | |
| Zhao et al. | Leveraging Extracellular Non-coding RNAs to Diagnose and Treat Heart Diseases | |
| EP2592145A1 (en) | Medicament for the treatment of cardiac disease | |
| JP6155191B2 (ja) | ＲＮＡ干渉によるｍＲＮＡ発現の抑制を促進する促進剤およびその用途 | |
| Pokhrel et al. | MicroRNA and Its Role in Cardiovascular |